Given the short therapeutic window available with the fast growing LLC tumour model, and since the Nk4 transgene product is secreted by transduced cells, we opted to administer AAV2-Nk4 prior to tumour induction, to quadriceps muscle, with the aim of producing systemic circulating Nk4 protein. This evidence concerns the gene IL32 and neoplasm.